The Medicines Health Regulatory Authority (MHRA) confirmed that it was safe to resume trials in a boost to the UK's efforts to secure a COVID-19 vaccine.
The company said that that the "standard review process triggered a voluntary pause" to all global trials on September 6 so that independent committees and internal regulators could review the safety data.
Talking about the development, UK's Secretary of State for Health Matt Hancock wrote on Twitter, "Good news for everyone the Oxford vaccine trials are back up and running".
And with billions still suffering from the fallout of the pandemic, a worldwide race for a vaccine is underway, with nine companies already in late-stage Phase 3 trials.
Following a standard review process, AstraZeneca paused all global trials on September 6 after an unidentified illness was reported in one of the trial participants.
In a statement, the university said that in large trials "it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety".
After the pause, AstraZeneca had said it remained hopeful that the vaccine could still be available "by the end of this year, early next year".
He noted the controversies surrounding vaccine production bordering on ethical issues, adding, "They relate to research and testing, informed consent and equitable distribution of the vaccines".
As part of the review process, independent boards overseeing trials of a number of other Covid-19 vaccines were analyzing their own data, looking for cases.
TikTok Negotiates with Feds to Avoid Complete Sale of U.S. Operations
But it's also unclear if the ban would prevent Apple, a United States company, from offering TikTok in its App Store overseas. Despite TikTok being in talks with firms like Microsoft , any deal must be decided by the September 20 deadline.
AstraZeneca announced on Wednesday it had "voluntarily paused" its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness.
But pharmaceutical companies including AstraZeneca and scientists have expressed concern about political pressure to rush a vaccine out, not least from US President Donald Trump.
Experts suggest that most of Covid-19 vaccine candidates being developed by academic laboratories and non-vaccine companies, who don't have the required infrastructure will have no choice but to partner with India or China.
The AZD1222, formerly known as ChAdOx1 nCoV-19, is a weakened form of the common cold virus that has been genetically moderated so that it can not grow in humans.
These were the details of the news Covid-19: Oxford vaccine trial resumes as coronavirus continues grim march for this day.
Health Minister Greg Hunt says there is genuine hope a vaccine being developed in the United Kingdom will be available in the first half of next year.
Russian Federation has touted Sputnik as the first vaccine against coronavirus to be registered in the world, even though Phase III trials have yet to be completed.
Although initial studies didn't reveal serious side effects from the vaccine, rare complications of any vaccine, if there are any, may not turn up until it has been administered to thousands, or tens or thousands of people.